Levonorgestrel/Ethinylestradiol Focus (Ethinylestradiol, Levonorgestrel)

Levonorgestrel/Ethinylestradiol is a combined oral contraceptive used to prevent unintended pregnancy and manage hormone‑related menstrual conditions.

• Contraception: provides reliable prevention of pregnancy for women of childbearing potential.
• Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual irregularities.
• Acne treatment: decreases androgen‑driven skin lesions in women requiring hormonal regulation.

• Levonorgestrel/Ethinylestradiol combines a synthetic progestogen (levonorgestrel) with an estrogen (ethinylestradiol). The estrogen stabilizes the endometrial lining while the progestogen suppresses the mid‑cycle luteinizing hormone surge, thereby inhibiting ovulation. Together they thicken cervical mucus and alter the endometrium, creating conditions unfavorable for fertilization and implantation. These hormonal actions are sustained throughout the 21‑day active phase of the monthly regimen, providing continuous contraceptive effect.

Levonorgestrel/Ethinylestradiol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset, often transient.
• Breast tenderness: temporary swelling or discomfort.
• Headache: mild to moderate intensity.
• Spotting between periods: irregular light bleeding.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in deep veins.
• Pulmonary embolism: clot migration to lung arteries.
• Stroke: cerebrovascular accident due to clot or hemorrhage.
• Myocardial infarction: heart attack risk, especially in smokers.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Liver tumor: rare hepatic adenoma development.

Before prescribing Levonorgestrel/Ethinylestradiol, clinicians should evaluate several safety considerations.

• Smoking: avoid use in women over 35 who smoke due to increased thrombotic risk.
• History of thromboembolism: contraindicated in patients with prior deep vein thrombosis or